Nurix Therapeutics (NRIX) Price & Analysis

Compare

454 Followers

NRIX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$8.18 - $29.56

Previous CloseN/A

Volume302.00K

Average Volume (3M)907.10K

Market Cap

$752.26M

Enterprise Value$457.82M

Total Cash (Recent Filing)$485.78M

Total Debt (Recent Filing)$51.93M

Price to Earnings (P/E)―

Beta2.18

Next Earnings

Oct 09, 2025

EPS Estimate

-0.81

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.52

Shares Outstanding76,449,356

10 Day Avg. Volume768,695

30 Day Avg. Volume907,101

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.61

Enterprise Value/Revenue5.18

Enterprise Value/Gross Profit12.70

Enterprise Value/Ebitda-2.10

Forecast

1Y Price Target

$27.54

Price Target Upside179.88% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering14

Bulls Say, Bears Say

Bulls Say

Clinical UpdatesThe data demonstrated continued deepening of responses in the CLL cohort, with an overall response rate reaching 81% and no new safety signals identified.

Financial PerformanceNurix reported $44.1M in collaboration/license revenue, exceeding previous estimates of $25.0M.

Regulatory DevelopmentsClarity on bexdeg's regulatory path in CLL is expected to be a positive for shares.

Bears Say

Market PerformanceShares are down -35% as investors await clarity on the future regulatory strategy for bexdeg in CLL.

Operational ExpensesAnalyst slightly lowers the 12-month price target to $34 from $36 due to greater operating expenses.

Regulatory RisksRisks include negative clinical proof-of-concept and failure to obtain timely approval for pipeline candidates.

Nurix Therapeutics News

Nurix Therapeutics price target lowered to $30 from $32 at Oppenheimer

Oppenheimer lowered the firm’s price target on Nurix Therapeutics (NRIX) to $30 from $32 and keeps an Outperform...

11d ago

NRIX

Nurix Therapeutics price target lowered to $16 from $17 at Morgan Stanley

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Nurix Therapeutics (NRIX) to $16 from $17...

27d ago

NRIX

Nurix Therapeutics price target lowered to $34 from $36 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Nurix Therapeutics (NRIX) to $34 from $36 and keeps a...

28d ago

NRIX

Buy Rating for Nurix Therapeutics Driven by Strong Financials and Upcoming Clinical Milestones

Analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Nurix Therapeutics, reducing the price target to...

28d ago

NRIX

Top 3 Trending Stocks, According to Analysts – 7/11/2025

Wondering which stocks are trending today? TipRanks has calculated which stocks have received the greatest number of new...

1M ago

NRIX

RARE

Optimistic Buy Rating for Nurix Therapeutics Amid Regulatory and Strategic Catalysts

Analyst Derek Archila from Wells Fargo reiterated a Buy rating on Nurix Therapeutics and keeping the price target...

1M ago

NRIX

Nurix Therapeutics price target lowered to $30 from $32 at Oppenheimer

Oppenheimer analyst Matthew Biegler lowered the firm’s price target on Nurix Therapeutics (NRIX) to $30 from $32 and...

1M ago

NRIX

Nurix Therapeutics: Strategic Advancements and Promising Pipeline Drive Buy Rating

In a report released yesterday, Jeet Mukherjee from BTIG maintained a Buy rating on Nurix Therapeutics, with a...

1M ago

NRIX

Positive Outlook for Nurix Therapeutics: Strong Financials and Promising Clinical Progress Support Buy Rating

Analyst Gil Blum of Needham maintained a Buy rating on Nurix Therapeutics, retaining the price target of $27.00....

1M ago

NRIX

Nurix Therapeutics price target lowered to $26 from $30 at UBS

UBS lowered the firm’s price target on Nurix Therapeutics (NRIX) to $26 from $30 and keeps a Buy...

1M ago

NRIX

Nurix Therapeutics Reports Increased Revenue Amid Net Loss

Nurix Therapeutics, Inc. ( ($NRIX) ) has released its Q2 earnings. Here is a breakdown of the information...

1M ago

NRIX

Closing Bell Movers: Ultragenyx slumps 25% on UX143 recommendation

In the opening hour of the evening session, U.S. equity futures are little changed, with S&P 500 above...

1M ago

KLG

MEI

Nurix Therapeutics reports Q2 EPS (52c), consensus (74c)

Reports Q2 revenue $44.1M, consensus $17.51M. The increase in revenue was primarily due to $30M of license revenue...

1M ago

NRIX

NRIX Earnings this Week: How Will it Perform?

Nurix Therapeutics, Inc. (NRIX) is scheduled to report 2nd quarter earnings on 07/10/2025. Regarding Q2 estimates, Wall Street...

1M ago

NRIX

NRIX FAQ

What was Nurix Therapeutics, Inc.’s price range in the past 12 months?

Nurix Therapeutics, Inc. lowest stock price was $8.18 and its highest was $29.56 in the past 12 months.

What is Nurix Therapeutics, Inc.’s market cap?

Nurix Therapeutics, Inc.’s market cap is $752.26M.

When is Nurix Therapeutics, Inc.’s upcoming earnings report date?

Nurix Therapeutics, Inc.’s upcoming earnings report date is Oct 09, 2025 which is in 59 days.

How were Nurix Therapeutics, Inc.’s earnings last quarter?

Nurix Therapeutics, Inc. released its earnings results on Jul 09, 2025. The company reported -$0.52 earnings per share for the quarter, beating the consensus estimate of -$0.719 by $0.199.

Is Nurix Therapeutics, Inc. overvalued?

According to Wall Street analysts Nurix Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Nurix Therapeutics, Inc. pay dividends?

Nurix Therapeutics, Inc. does not currently pay dividends.

What is Nurix Therapeutics, Inc.’s EPS estimate?

Nurix Therapeutics, Inc.’s EPS estimate is -0.81.

How many shares outstanding does Nurix Therapeutics, Inc. have?

Nurix Therapeutics, Inc. has 76,449,356 shares outstanding.

What happened to Nurix Therapeutics, Inc.’s price movement after its last earnings report?

Nurix Therapeutics, Inc. reported an EPS of -$0.52 in its last earnings report, beating expectations of -$0.719. Following the earnings report the stock price went down -3.869%.

Which hedge fund is a major shareholder of Nurix Therapeutics, Inc.?

Currently, no hedge funds are holding shares in NRIX

Nurix Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-50.67%

Trailing 12-Months

Asset Growth

15.76%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. (NRIX) is a biopharmaceutical company based in the United States that focuses on the discovery, development, and commercialization of therapies targeting the ubiquitin proteasome system. The company operates in the biotechnology sector and primarily develops products that aim to treat cancer and other challenging diseases through the modulation of protein levels using its proprietary drug discovery platform, DELigase. Nurix's core products are in the preclinical and clinical stages of development, targeting various oncology and immuno-oncology indications.

Nurix Therapeutics (NRIX) Earnings & Revenues

Historic Earnings Reports

NRIX Stock 12 Month Forecast

Average Price Target

$27.54

▲(179.88% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","16":"$16","23":"$23","30":"$30","37":"$37"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$36.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27.54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$27.54</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,16,23,30,37],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.04,12.959999999999999,14.879999999999999,16.8,18.72,20.64,22.560000000000002,24.48,26.4,28.32,30.240000000000002,32.16,34.08,{"y":36,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.04,12.30923076923077,13.578461538461537,14.847692307692306,16.116923076923076,17.386153846153846,18.655384615384612,19.924615384615382,21.193846153846152,22.463076923076922,23.732307692307693,25.00153846153846,26.27076923076923,{"y":27.54,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.04,11.075384615384614,11.11076923076923,11.146153846153846,11.18153846153846,11.216923076923077,11.252307692307692,11.287692307692307,11.323076923076922,11.358461538461539,11.393846153846154,11.429230769230768,11.464615384615385,{"y":11.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.47,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.2,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.09,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.47,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.49,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.71,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.47,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.16,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.04,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >